TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CF~* Homozygous for the F508del CFTR mutation~* Forced expiratory volume in 1 second (FEV1) greater than or equal to (\>=) 40 percent (%) and less than or equal to (=\<) 90% of predicted normal for age, sex, and height~* Willing to remain on a stable CF medication regimen through Week 24 or, if applicable, the Safety Follow up Visit~Exclusion Criteria:~* An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before first dose of study drug~* History of solid organ or hematological transplantation~* History of alcohol or drug abuse in the past year~* Ongoing or prior participation in an investigational drug study (including studies investigating lumacaftor and/or ivacaftor) within 30 days of screening~* Use of strong inhibitors, moderate inducers or strong inducers of Cytochrome P450 3A (CYP3A) within 14 days before Day 1 of dosing

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.
- LUM 600 mg qd/IVA 250 mg q12h (Type: EXPERIMENTAL): LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.
- LUM 400 mg q12h/ IVA 250 mg q12h (Type: EXPERIMENTAL): LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Patients with symptomatic Dry eye~  * Shirmer ≤10 mm in 5 min~ * BUT ≤10 seconds~ * Corneal staining ≥3~ * Age range: 18 years and older.~ * Both genders and all ethnic groups comparable with the local community.~ * Able to understand and willing to sign a written informed consent~ * Able and willing to cooperate with the investigational plan.~ * Able and willing to complete all mandatory follow-up visits.~Exclusion Criteria:~* • Patients who are currently engaged in another clinical trial, unwilling or unable to give consent, to accept randomization, or to return for scheduled visits.~  * Children under 18.~ * Pregnant women or expecting to be pregnant during the study.~ * Systemic immune deficient conditions such as AIDS or under systemic immunosuppressant.~ * Concomitant use of systemic antibiotics or steroids.~ * Contact lens wear~ * Active ocular infection or allergy~ * Unable to close eyes or uncontrolled blinking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Platelet -Rich Plasma (PRP) (Type: EXPERIMENTAL): 15 patients with diagnosis of severe dry eye will receive PRP injection at day 0, 30,60 and 90
- Standard Care (Type: ACTIVE_COMPARATOR): 15 patients with diagnosis of severe dry eye will receive standard of care treatment and will be revised at day 0, 30,60,90

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women of 18 years of age or older.~* T-score by Dual X-ray Absorptiometry (DXA) between -1,0 og -3,5~* Patients from The North Jutland Region diagnosed with primary hyperparathyroidism at the Department of Endocrinology, Aalborg University Hospital. (Hypercalcaemia measured at two different time-points and simultaneous elevated/inappropriately high PTH, and exclusion of differential diagnosis.)~Exclusion Criteria:~* Medical history of diseases leading to hypercalcaemia other than Primary Hyperparathyroidism.~* Patients being treated with Denosumab or Cinacalcet prior to inclusion or previously treated with Denosumab or Cinacalcet.~* Moderately - Severely decreased liver function (alanine aminotransferase \>250u/l, gamma-glutamyl transferase\>150u/l, Bilirubin \>30)~* Acute myocardial infarction or apoplexia in the 3 months before inclusion.~* Medical record of heart failure~* Risk factors of prolonged corrected QT interval (QTc).~* Open lesions from oral surgery.~* Primary diseases of the bone other than osteoporosis.~* Patients suffering from kidney disease or renal failure.~* Patients under treatment with thiazide or lithium.~* Medical record of generalized seizures or epilepsy.~* Active malignant disease.~* Known allergies towards the specified medicinal products (IMPs).~* Pregnancy or breastfeeding.~* Fertile women who do not agree to the usage of effective contraception.~* Other circumstances, evaluated by the responsible investigator, making the subject unsuitable for participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combined treatment. (Type: EXPERIMENTAL): 20 subjects will be treated with combined 60mg denosumab bi-annually , 30 mg cinacalcet daily and 50 micrograms vitamin-D daily.
- Monotherapy (Type: ACTIVE_COMPARATOR): 20 subjects will receive 60mg denosumab bi-annually, placebo and 50 micrograms vitamin-D daily.
- Placebo (Type: PLACEBO_COMPARATOR): 20 subjects will receive a saline injection bi-annually (blinded), placebo-tablets and 50 micrograms vitamin-D daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adult (≥ 60 years)~2. Subject is contractually capable, able to understand information on study and has signed informed consent sheet~3. Subject has access to an internet-enabled electronic device~Exclusion Criteria:~1. Known active or latent Mycobacterium tuberculosis infection~2. Fever (\> 38 °C) or respiratory tract infection within the past 24 hours~3. Current active viral or bacterial infection~4. Expected vaccination during the study period; vaccinations against influenza and pneumococcal disease are allowed with ≥ 4 weeks between these vaccinations and the trial vaccination~5. Participation in another interventional study within 30 days before screening and during this study~6. Known hypersensitivity or allergy to (components of) the VPM1002 vaccine or serious adverse reactions to prior Bacille Calmette-Guérin (BCG) administration~7. Severely immunocompromised subjects, including:~   1. subjects with known infection by the human immunodeficiency virus (HIV-1);~  2. subjects with solid organ transplantation;~  3. subjects with bone marrow transplantation;~  4. subjects under chemotherapy, immunotherapy, or radiotherapy;~  5. subjects with primary immunodeficiency;~  6. treatment with any anti-cytokine therapies;~  7. treatment with oral or intravenous steroids defined as daily doses of 10 mg prednisone or equivalent for longer than 3 months, or likely use of oral or intravenous steroids in the next 4 weeks;~8. History of malignancies, unless the subject has been free of the disease for ≥ 2 years; exception: subjects with adequately treated basal or squamous cell cancer or other localized non-melanoma skin cancer and adequately treated carcinoma in situ of the cervix may participate in the trial~9. Previous positive SARS-CoV-2 test result~10. Person is an employee of the sponsor, a relative of the sponsor or investigator, or is employed in the same department as the investigator

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- VPM1002 (Type: EXPERIMENTAL): The active ingredient of the recombinant BCG vaccine, VPM1002, is Mycobacterium bovis rBCGΔureC::hly, freeze-dried and standardized to the number of viable mycobacteria (colony forming units; CFU) per application.~Dose: 2-8 x 10e5 CFU VPM1002 administered in 0.1 ml reconstituted suspension.
- Placebo (Type: PLACEBO_COMPARATOR): Physiological saline 0.1ml

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females, 18 to 65 years of age.~2. FEV1 60-85% of predicted on the screening day. -~Exclusion Criteria:~1. Women of childbearing potential who do not use accepted birth control measures; pregnant and breast feeding women. 2. Cardiovascular disease and/or use of cardiovascular medications 3. Subjects with known beta-adrenergic agonist or glucocorticosteroid intolerance 4. Acute respiratory infection within four weeks prior to the study 5. Use, within two weeks prior to the study, of any anti-asthma medication not mentioned above~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- fluticasone/salmeterol (Type: EXPERIMENTAL): participants were treated fluticasone/salmeterol,
- salmeterol (Type: EXPERIMENTAL): participants were treated with salmeterol
- fluticasone (Type: EXPERIMENTAL): participants were treated with fluticasone
- placebo inhalation (Type: PLACEBO_COMPARATOR): participants were treated with placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients at least 18 years of age with moderate to severe active RA for at least 6 months;~* inadequate response to current anti-rheumatic therapies, including MTX;~* inadequate response or intolerance to treatment with 1 or more anti-TNF therapies within 1 year of entering study;~* on stable MTX for at least 8 weeks before entering study;~* patients of reproductive potential must be using reliable methods of contraception.~Exclusion Criteria:~* major surgery (including joint surgery) within 8 weeks before screening, or planned major surgery within 6 months after entering study;~* women who are pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with end-stage kidney disease (ESKD) on dialysis (including, hemodiafiltration, hemodialysis, and other modalities except for peritoneal dialysis) weekly or more than weekly~* Body weight \> 40 and ≤ 160 kg at screening~* Male or female subject ≥ 20 years of age at screening~* At least one kidney~* Not treated with ESAs and/or HIF-PH inhibitors within 8 weeks prior to randomization. However, in case of the patient washed out from ESAs, when the mean Hb (at least 2 central laboratory measurements must be taken ≥ 2 days apart before dialysis) has decrease to ≥ 0.5 dL from the Hb level (central laboratory measurement, before dialysis) after the last ESA administration, AND the interval from the last ESA administration to the study drug assignment was over 1 week for epoetin-alpha, 2 weeks for darbepoetin alpha or 4 weeks for epoetin beta pegol~* Mean of the last 2 Hb level (central laboratory measurement, before dialysis) during the screening period must be ≥ 8.0 and \< 10.0 g/dL (2 measurements must be taken ≥ 2 days apart and the difference between the 2 measurements must be \< 1.2 g/dL) with the last screening Hb measurement within 14 days prior to study drug assignment~* Ferritin ≥ 50 ng/mL at screening~Exclusion Criteria:~* New York Heart Association (NYHA) Class III or IV congestive heart failure~* History of cardio- (cerebro-) vascular events (e.g., unstable angina, myocardial infarction, stroke, pulmonary thromboembolism, and acute limb ischemia) within 6 months prior to randomization~* Sustained and poorly controlled arterial hypertension (defined as systolic BP≥ 180mmHg or diastolic BP ≥ 110mmHg) or hypotension (defined as systolic BP \< 90mmHg) at randomization~* Proliferative choroidal or retinal disease, such as neovascular age-related macular degeneration or proliferative diabetic retinopathy requiring invasive treatment (e.g., intraocular injections or laser photocoagulation)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Molidustat (BAY85-3934) (Type: EXPERIMENTAL): Molidustat group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed prostate cancer with progressive disease~* Evidence of castration resistance defined as disease progression despite a testosterone level \< 50ng/dL (or surgical castration)~* Evidence of metastatic disease to the bones within the lumbar spine, sacrum, or pelvic bones that is identifiable on screening pelvic MRI~* If patient has had prior pelvis radiation therapy (RT), then bone metastases must be out of radiated port (e.g. lumbar or sacral spine)~* Any prior therapy for castrate disease acceptable other than prior XL184 with a minimum washout of 28 days for any other anticancer therapy~* Patients with castrate resistant disease post antiandrogen therapy/withdrawal must meet at least one of the following criteria:~  * Have not received docetaxel chemotherapy~ * Have received docetaxel chemotherapy but received less then 225mg/m2 cumulative dose~ * Have documented liver metastases~ * Have no pain or pain that does not require a long acting (SR) narcotic~ * Have received mitoxantrone chemotherapy in the past for CRPC~Exclusion Criteria:~* Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study~* Patients who are receiving any other investigational agents~* Prior treatment with other vascular endothelial growth factor (VEGF) or c-MET targeted therapies~* History of hematemesis or hemoptysis~* The subject has uncontrolled or significant intercurrent illness~* The patient requires concomitant treatment, in therapeutic doses, with anticoagulants

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (enzyme inhibitor therapy) (Type: EXPERIMENTAL): Patients receive cabozantinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TAilored Post-Surgical Therapy in Early Stage NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NSCLC that is defined as other than predominantly squamous cell histology (squamous cell and/or mixed small cell, non-small cell histology is not permitted)~* Surgically resected NSCLC with pathological stage II or stage IIIA non-N2 (TNM classification 2008)~* Performance status (PS) = 0 or 1~* 18 years \<= age \< 70 years~* Signed inform consent~Exclusion Criteria:~* Squamous cell carcinoma~* Previous cancer excepted those treated for more than 5 years and considered cured, basocellular skin carcinoma, carcinoma in situ of uterine cervix~* Inadequate renal or cardiac functions~* Pregnant women~* Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart failure, cerebrovascular accident or transient ischemic attack, grade ≥ 2 peripheral neuropathy, peptic ulcer disease, erosive esophagitis or gastritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Standard chemotherapy
- B (Type: EXPERIMENTAL): Customized treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Dementia of the Alzheimer's type with behavioral disturbance, vascular dementia with behavioral disturbance, or mixed dementia, as classified by DSM-IV (the Diagnostic and Statistical Manual of Mental Diseases, 4th edition)~* a score \>=4 on the FAST (Functional Assessment Staging, a diagnosis tool for determining the stage of dementia) and a score \<=23 on the MMSE (Mini-Mental State Examination, a clinical measure used to evaluate cognition)~* a BEHAVE-AD (Behavior Pathology in Alzheimer's Disease Rating Scale) total score \>=8, and a BEHAVE-AD global rating \>=1~* patient must be living in an nursing home for \>=1 month. Exclusion Criteria:~* Patients with other medical or neurological conditions other than dementia in which cognition is diminished (for example, severe anemia, severe liver, heart, lung, and kidney malfunctions, Parkinson's disease)~* diagnosis of depression within the 6 months before study entry, schizophrenia, bipolar affective disorder, or schizoaffective disorder~* history of or moderate to severe tardive dyskinesia, (a condition of uncontrollable movements of the tongue, lips, face, trunk, hands and feet that is seen in patients receiving long-term medication with certain types of antipsychotic drugs)~* abnormal clinical laboratory test findings.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Supra-inguinal Fascia Iliaca Compartment Block on Postoperative Management in Total Hip Arthroplasty by Posterior Approach

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults patients scheduled to undergo elective surgery of total hip arthroplasty by posterior surgical aboard~Exclusion Criteria:~* Patient refusal~* Allergy to used medications or local infection.~* Pregnancy~* Obesity with body mass index \> 35~* History of chronic pain or fibromyalgia~* Drug (opioids) addiction~* Treatment with corticosteroids for more than 6 months~* Severe kidney or liver diseases~* Mental disorders or serious neurological diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo group: patients have multimodal analgesia without fascia-iliaca compartment block
- Fascia iliaca block (Type: EXPERIMENTAL): Patients in this arm have multimodal analgesia with supra-inguinal fascia iliaca compartment block before surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Vaginal Progesterone and Cerclage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age from 20 - 35 years old.~* Pregnant from (12- 14 weeks) gestation.~* Singleton pregnancy.~* The pregnant women who have a history of second trimester pregnancy loss with painless cervical dilatation or have prior cerclage placement for cervical insufficiency or have a history of spontaneous preterm.~Exclusion Criteria:~* Multiple gestations.~* Congenital fetal malformation in the current pregnancy.~* Women with history of thromboembolism or bleeding disorders.~* Uncontrolled diabetes mellitus.~* Chromosomal abnormalities affecting one of the couples.~* Women refuse to participate in the study~* Antiphospholipid syndrome

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Vaginal progesterone group (Type: ACTIVE_COMPARATOR): Will receive progesterone pessaries 400 mg once daily vaginally
- No progesterone group (Type: NO_INTERVENTION): Will receive nothing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete